Matthew Barcus
Stock Analyst at Chardan Capital
(2.36)
# 2,329
Out of 4,820 analysts
21
Total ratings
25%
Success rate
18.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $1.44 | +594.44% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $14.28 | +89.08% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.83 | +740.24% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $15.09 | +112.06% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $2.75 | +7,900.00% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $2.78 | +223.74% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $8.54 | -6.27% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $1.44
Upside: +594.44%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $14.28
Upside: +89.08%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.83
Upside: +740.24%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $15.09
Upside: +112.06%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $2.75
Upside: +7,900.00%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $2.78
Upside: +223.74%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $8.54
Upside: -6.27%